Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Alignment Healthcare Inc (NASDAQ: ALHC) was $21.0 for the day, up 3.86% from the previous closing price of $20.22. In other words, the price has increased by $3.86 from its previous closing price. On the day, 3.07 million shares were traded. ALHC stock price reached its highest trading level at $21.18 during the session, while it also had its lowest trading level at $19.83.
Ratios:
Our analysis of ALHC’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 2.04 whereas as Long-Term Debt/Eq ratio is at 2.04.
On October 14, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $21.
KeyBanc Capital Markets Upgraded its Sector Weight to Overweight on August 25, 2025, while the target price for the stock was maintained at $21.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 29 ’25 when Scavo Robert L. sold 69,541 shares for $18.74 per share. The transaction valued at 1,303,384 led to the insider holds 503,014 shares of the business.
Kim Hyong sold 12,694 shares of ALHC for $237,920 on Dec 29 ’25. The Chief Medical Officer now owns 349,639 shares after completing the transaction at $18.74 per share. On Dec 29 ’25, another insider, KAO JOHN E, who serves as the Chief Executive Officer of the company, sold 605,648 shares for $18.74 each. As a result, the insider received 11,351,467 and left with 2,234,294 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 4201926656 and an Enterprise Value of 3887504640. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.16 while its Price-to-Book (P/B) ratio in mrq is 25.95. Its current Enterprise Value per Revenue stands at 1.069 whereas that against EBITDA is 109.637.
Stock Price History:
The Beta on a monthly basis for ALHC is 1.16, which has changed by 0.72378516 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, ALHC has reached a high of $21.06, while it has fallen to a 52-week low of $11.30. The 50-Day Moving Average of the stock is 14.56%, while the 200-Day Moving Average is calculated to be 28.02%.
Shares Statistics:
ALHC traded an average of 2.54M shares per day over the past three months and 2717720 shares per day over the past ten days. A total of 199.99M shares are outstanding, with a floating share count of 173.60M. Insiders hold about 13.24% of the company’s shares, while institutions hold 87.25% stake in the company. Shares short for ALHC as of 1765756800 were 16037111 with a Short Ratio of 6.30, compared to 1763078400 on 13982386. Therefore, it implies a Short% of Shares Outstanding of 16037111 and a Short% of Float of 12.280000000000001.
Earnings Estimates
The dynamic stock of Alignment Healthcare Inc (ALHC) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.13, with high estimates of $0.13 and low estimates of $0.13.
Analysts are recommending an EPS of between $0.28 and $0.19 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is $0.41, with 4.0 analysts recommending between $0.46 and $0.35.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 11 analysts. It ranges from a high estimate of $1.01B to a low estimate of $998.6M. As of. The current estimate, Alignment Healthcare Inc’s year-ago sales were $701.24MFor the next quarter, 11 analysts are estimating revenue of $1.22B. There is a high estimate of $1.28B for the next quarter, whereas the lowest estimate is $1.17B.
A total of 11 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $3.95B, while the lowest revenue estimate was $3.93B, resulting in an average revenue estimate of $3.94B. In the same quarter a year ago, actual revenue was $2.7BBased on 11 analysts’ estimates, the company’s revenue will be $5.14B in the next fiscal year. The high estimate is $5.39B and the low estimate is $4.93B.
